prifemilast
Asset
Inhibits PDE4, increasing intracellular cyclic AMP and suppressing inflammatory signaling.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Psoriasis
Phase 3, prnewswire.com, 9 Oct 2026
In the full profile
- Targets and what it contains5
- Owner and partners2
- Evidence for its targets5
- Competitors7
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.